Epizyme (EPZM) Highlighted on Sector Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailEpizyme (NASDAQ: EPZM) highlighted as a comp for MyoKardia (NASDAQ: MYOK), which was acquired today, at Citi. Sees EPZM worth $45-$55 in a deal.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DoorDash in advanced talks to acquire Instacart, WSJ reports
- Kotak Upgrades SBFC Finance Ltd (SBFC:IN) to Buy (1)
- JPMorgan Upgrades KEI Industries Ltd (KEII:IN) to Overweight
Create E-mail Alert Related Categories
Analyst Comments, Rumors, Trader TalkRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
